- Published on
Ophthalmology – Achromatopsia
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
Achromatopsia is a congenital retinal disorder characterized by reduced or absent color vision due to defective cone photoreceptor function. It presents with photophobia, decreased visual acuity, nystagmus, eccentric fixation, and a small central scotoma. The condition may be classified into complete and incomplete forms, depending on the degree of residual cone function. It typically manifests in infancy, often with fine nystagmus and marked light sensitivity, and children may prefer dim lighting, sometimes being described as “night owls.” Visual acuity is usually reduced, commonly around 20/200, and color discrimination is severely impaired.
The condition has an estimated incidence of approximately 1 in 30,000 individuals and follows an autosomal recessive inheritance pattern. Risk factors include consanguinity and a positive family history. Several genetic mutations have been identified, including CNGA3, CNGB3 (notably the Pingelap variant), GNAT2, and others, all affecting proteins involved in cone phototransduction. The underlying pathophysiology involves reduced or absent expression of these proteins in cone photoreceptors, leading to disruption of the normal phototransduction cascade and abnormal cone development.
Clinically, patients exhibit high-frequency nystagmus that may lessen with age, significant photophobia, and reduced visual acuity. Hyperopia may be present, and fundus examination is often normal or shows only subtle changes such as minimal foveal hypoplasia or mild pigmentary alterations. Color vision testing reveals impairment across all axes (protan, deutan, and tritan). Full-field electroretinography typically demonstrates absent or markedly reduced photopic (cone-mediated) responses with relatively preserved scotopic (rod-mediated) responses. Visual field testing may show a small central scotoma, and optical coherence tomography may appear normal or show mild macular thinning. Additional imaging such as fluorescein angiography and fundus autofluorescence is usually normal.
Diagnosis is supported by clinical findings and can be confirmed with molecular genetic testing. Neuroimaging may be considered in atypical cases, particularly when nystagmus presentation is unusual, to exclude intracranial pathology. Histopathologically, there is a reduced number of cones, and the remaining cones are structurally abnormal.
Differential diagnoses include incomplete achromatopsia, which retains partial cone function and better visual acuity; blue-cone monochromatism, which is X-linked and can be differentiated by specialized color testing or electroretinography; cone monochromatism; cone dystrophy, which shows progressive deterioration rather than congenital onset; and cone-rod dystrophy, which includes rod involvement over time. Other considerations include foveal hypoplasia and cerebral achromatopsia, the latter typically associated with neurological events such as trauma or febrile illness.
There is no specific medical treatment for achromatopsia. Management focuses on supportive measures, including the use of dark or tinted glasses or red-tinted contact lenses to reduce photophobia, although these may not always be well tolerated. Low vision aids are beneficial, and children may require educational support such as individualized learning plans. Correction of refractive error is important, and patients should be referred for genetic counseling and low vision services as needed.
Regular follow-up is recommended, particularly in children, with ophthalmic evaluations every 6 to 12 months to monitor visual function and refractive status. The prognosis is generally stable, with visual acuity remaining relatively constant over time, although mild degeneration may occur later in life due to age-related photoreceptor loss. Nystagmus and photophobia may improve slightly with age. The main complications include persistent low vision and significant light sensitivity, which can impact daily functioning and quality of life.
- Published on
Ophthalmology – Abducens (Cranial Nerve VI) Palsy
Abducens nerve (cranial nerve VI) palsy is the most common isolated cranial nerve palsy and affects the lateral rectus muscle, which is responsible for abducting the eye. Dysfunction of this nerve results in binocular horizontal diplopia and esotropia, typically worse when looking toward the affected side and at distance. Children may not complain of diplopia. The nerve originates from the dorsal lower pons, where its nucleus contains motor neurons supplying the ipsilateral lateral rectus and interneurons that project via the medial longitudinal fasciculus to coordinate horizontal gaze. Lesions at the nuclear level produce a gaze palsy rather than an isolated nerve palsy. The nerve exits at the pontomedullary junction, travels along the clivus, passes through Dorello’s canal at the petrous apex, courses within the cavernous sinus adjacent to the internal carotid artery, and enters the orbit via the superior orbital fissure.
This condition can occur at any age, although its causes vary with age group. The incidence is approximately 11 per 100,000, with peak occurrence in the seventh decade, and there is no clear sex or racial predilection. In adults over 50 years, the most common cause is microvascular ischemia, particularly associated with diabetes, which is the strongest independent risk factor. Other contributing factors include hypertension, hyperlipidemia, obesity, trauma, and alcohol abuse, the latter being linked to conditions such as Wernicke-Korsakoff syndrome due to thiamine deficiency. In children, abducens nerve palsy is more concerning, as it is frequently associated with intracranial tumors, along with trauma and increased intracranial pressure, and may occasionally follow viral illness.
Pathophysiologically, lesions can occur anywhere along the course of the nerve. In the pons, causes include demyelination, infarction, and neoplasms. At the cerebellopontine angle, tumors such as acoustic neuromas may affect the nerve root. Within the subarachnoid space, causes include aneurysms, meningitis, infections, inflammation, and neoplasms. At the petrous ridge, conditions such as recurrent otitis media, nasopharyngeal carcinoma, or chondrosarcoma may be implicated. In the cavernous sinus, pathology may include thrombosis, fistula, aneurysm, or tumors, often affecting multiple cranial nerves. Orbital apex or orbital involvement may result from inflammatory, infectious, or neoplastic processes. Etiologies broadly include ischemic, compressive, inflammatory, traumatic, and pressure-related causes, as well as demyelinating diseases like multiple sclerosis.
Congenital and pediatric forms include rare isolated congenital absence of abduction, transient palsy from birth trauma, Möbius syndrome characterized by facial diplegia and gaze abnormalities, and Duane’s retraction syndrome, which involves abnormal innervation of the lateral rectus and presents with globe retraction and palpebral fissure narrowing. Children most commonly develop abducens palsy due to tumors, trauma, or raised intracranial pressure.
Patients may present with a compensatory head turn toward the affected side and exhibit limited abduction of the involved eye, along with incomitant esotropia that worsens in the direction of action of the weak lateral rectus muscle. A thorough history should assess onset, associated pain, headache, trauma, hearing changes, and symptoms suggestive of giant cell arteritis. Clinical examination should include evaluation of all cranial nerves, assessment for papilledema, orbital examination, and tests such as forced duction and orbicularis oculi strength to exclude myasthenia gravis.
Investigations are guided by clinical presentation. Laboratory tests may include HbA1c, ESR and CRP for suspected giant cell arteritis, and anti-acetylcholine receptor antibodies for myasthenia gravis. Imaging is not required in all cases but is essential in non-isolated palsy, presence of neurological signs, orbital findings, or suspected raised intracranial pressure, typically using MRI, sometimes with MRV and lumbar puncture. In selected low-risk patients, especially older individuals with vascular risk factors, observation may be appropriate, with imaging reserved for lack of improvement after three months.
Differential diagnoses include myasthenia gravis, thyroid eye disease, orbital fractures, Duane’s retraction syndrome, and spasm of the near reflex. Management primarily focuses on identifying and treating the underlying cause. Symptomatic relief can be achieved with monocular occlusion or prisms, while botulinum toxin injection into the medial rectus may provide temporary improvement. Surgical intervention, such as lateral rectus resection and medial rectus recession or muscle transposition, is considered after 6 to 12 months if the deviation is stable.
Follow-up is essential, particularly in older patients with vascular risk factors, who should be reassessed within weeks and undergo imaging if symptoms worsen or fail to improve. Prognosis is generally favorable in ischemic cases, with most resolving within three to four months and a high rate of complete recovery. Children with isolated palsy also tend to recover within several months, while traumatic cases show variable recovery, with partial improvement in many and complete recovery in a smaller proportion. Important clinical considerations include the need to exclude non-neurological causes of abduction deficit, the significance of cavernous sinus involvement when multiple cranial nerves are affected, and the necessity of evaluating for papilledema and serious underlying conditions such as giant cell arteritis.
Abducens nerve (cranial nerve VI) palsy is the most common isolated cranial nerve palsy and affects the lateral rectus muscle, which is responsible for abducting the eye. Dysfunction of this nerve results in binocular horizontal diplopia and esotropia, typically worse when looking toward the affected side and at distance. Children may not complain of diplopia. The nerve originates from the dorsal lower pons, where its nucleus contains motor neurons supplying the ipsilateral lateral rectus and interneurons that project via the medial longitudinal fasciculus to coordinate horizontal gaze. Lesions at the nuclear level produce a gaze palsy rather than an isolated nerve palsy. The nerve exits at the pontomedullary junction, travels along the clivus, passes through Dorello’s canal at the petrous apex, courses within the cavernous sinus adjacent to the internal carotid artery, and enters the orbit via the superior orbital fissure.
This condition can occur at any age, although its causes vary with age group. The incidence is approximately 11 per 100,000, with peak occurrence in the seventh decade, and there is no clear sex or racial predilection. In adults over 50 years, the most common cause is microvascular ischemia, particularly associated with diabetes, which is the strongest independent risk factor. Other contributing factors include hypertension, hyperlipidemia, obesity, trauma, and alcohol abuse, the latter being linked to conditions such as Wernicke-Korsakoff syndrome due to thiamine deficiency. In children, abducens nerve palsy is more concerning, as it is frequently associated with intracranial tumors, along with trauma and increased intracranial pressure, and may occasionally follow viral illness.
Pathophysiologically, lesions can occur anywhere along the course of the nerve. In the pons, causes include demyelination, infarction, and neoplasms. At the cerebellopontine angle, tumors such as acoustic neuromas may affect the nerve root. Within the subarachnoid space, causes include aneurysms, meningitis, infections, inflammation, and neoplasms. At the petrous ridge, conditions such as recurrent otitis media, nasopharyngeal carcinoma, or chondrosarcoma may be implicated. In the cavernous sinus, pathology may include thrombosis, fistula, aneurysm, or tumors, often affecting multiple cranial nerves. Orbital apex or orbital involvement may result from inflammatory, infectious, or neoplastic processes. Etiologies broadly include ischemic, compressive, inflammatory, traumatic, and pressure-related causes, as well as demyelinating diseases like multiple sclerosis.
Congenital and pediatric forms include rare isolated congenital absence of abduction, transient palsy from birth trauma, Möbius syndrome characterized by facial diplegia and gaze abnormalities, and Duane’s retraction syndrome, which involves abnormal innervation of the lateral rectus and presents with globe retraction and palpebral fissure narrowing. Children most commonly develop abducens palsy due to tumors, trauma, or raised intracranial pressure.
Patients may present with a compensatory head turn toward the affected side and exhibit limited abduction of the involved eye, along with incomitant esotropia that worsens in the direction of action of the weak lateral rectus muscle. A thorough history should assess onset, associated pain, headache, trauma, hearing changes, and symptoms suggestive of giant cell arteritis. Clinical examination should include evaluation of all cranial nerves, assessment for papilledema, orbital examination, and tests such as forced duction and orbicularis oculi strength to exclude myasthenia gravis.
Investigations are guided by clinical presentation. Laboratory tests may include HbA1c, ESR and CRP for suspected giant cell arteritis, and anti-acetylcholine receptor antibodies for myasthenia gravis. Imaging is not required in all cases but is essential in non-isolated palsy, presence of neurological signs, orbital findings, or suspected raised intracranial pressure, typically using MRI, sometimes with MRV and lumbar puncture. In selected low-risk patients, especially older individuals with vascular risk factors, observation may be appropriate, with imaging reserved for lack of improvement after three months.
Differential diagnoses include myasthenia gravis, thyroid eye disease, orbital fractures, Duane’s retraction syndrome, and spasm of the near reflex. Management primarily focuses on identifying and treating the underlying cause. Symptomatic relief can be achieved with monocular occlusion or prisms, while botulinum toxin injection into the medial rectus may provide temporary improvement. Surgical intervention, such as lateral rectus resection and medial rectus recession or muscle transposition, is considered after 6 to 12 months if the deviation is stable.
Follow-up is essential, particularly in older patients with vascular risk factors, who should be reassessed within weeks and undergo imaging if symptoms worsen or fail to improve. Prognosis is generally favorable in ischemic cases, with most resolving within three to four months and a high rate of complete recovery. Children with isolated palsy also tend to recover within several months, while traumatic cases show variable recovery, with partial improvement in many and complete recovery in a smaller proportion. Important clinical considerations include the need to exclude non-neurological causes of abduction deficit, the significance of cavernous sinus involvement when multiple cranial nerves are affected, and the necessity of evaluating for papilledema and serious underlying conditions such as giant cell arteritis.
- Published on
Infectious Disease and Microbiology: Hemolytic–Uremic Syndrome (HUS)
Hemolytic–uremic syndrome (HUS) is a serious clinical condition characterized by a triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. It is most commonly associated with infection by Shiga toxin–producing bacteria, particularly Escherichia coli O157:H7 (EHEC). HUS primarily affects young children but can occur at any age and is a major cause of acute kidney injury in pediatric populations.
Epidemiologically, HUS is closely linked to infections caused by enterohemorrhagic E. coli, with an incidence of approximately 1–5 cases per 100,000 people annually in industrialized countries. The infection is more common in children under 5 years old and tends to peak during warmer months, particularly from June to September. Although many individuals infected with EHEC develop only mild gastrointestinal symptoms, about 8% of cases during outbreaks progress to HUS, especially in vulnerable populations such as young children and the elderly.
Transmission is primarily food-borne and is strongly associated with the consumption of undercooked ground beef, unpasteurized milk, contaminated water, and fresh produce such as apples or melons. Cattle serve as the main reservoir, often carrying the organism asymptomatically in their intestines. Infection can also spread through person-to-person contact, particularly in settings such as daycare centers and nursing homes. Proper food handling, cooking, and hygiene practices are essential preventive measures.
The pathophysiology of HUS involves the production of Shiga-like toxin by EHEC. This toxin damages endothelial cells, particularly in the kidneys, leading to inflammation, platelet activation, and formation of microthrombi in small blood vessels. These processes result in mechanical destruction of red blood cells (hemolysis), platelet consumption (thrombocytopenia), and reduced renal perfusion, ultimately causing acute kidney injury.
Clinically, infection typically begins with abdominal cramps and watery diarrhea, which progresses within 24 hours to bloody diarrhea in most patients. Nausea and vomiting are common, while fever is usually absent or mild. As HUS develops, signs such as decreased urine output (oliguria), pallor from anemia, and fatigue become evident. The drop in hematocrit and platelet count are early laboratory indicators of disease progression.
Diagnosis is based on clinical findings and laboratory confirmation. Stool cultures using special media are required to identify EHEC, as routine cultures may miss the organism. Laboratory findings in HUS include anemia with fragmented red blood cells (schistocytes), elevated lactate dehydrogenase (LDH), low haptoglobin, thrombocytopenia, and elevated creatinine levels indicating renal impairment. Urinalysis may show hematuria and proteinuria.
Management of HUS is primarily supportive. Antibiotics are generally not recommended in EHEC infections, as they may increase toxin release and worsen the condition. Similarly, antimotility agents should be avoided because they can enhance toxin absorption. Treatment focuses on maintaining fluid and electrolyte balance, managing renal failure with dialysis if necessary, and providing blood transfusions when indicated. In severe cases, plasmapheresis may be used.
The prognosis of HUS varies depending on severity and patient factors. Despite advances in supportive care, mortality rates range from 5% to 20%, with higher rates in older adults. Among survivors, long-term complications are common, including chronic kidney disease and hypertension, with many patients eventually requiring dialysis or kidney transplantation.
Complications of HUS include severe anemia, thrombocytopenia, electrolyte disturbances, rhabdomyolysis, and permanent renal damage. Additionally, EHEC infection itself may cause hemorrhagic colitis or, less commonly, conditions such as thrombotic thrombocytopenic purpura. Early recognition and supportive management are critical to improving outcomes.
- Published on
Infectious Disease and Microbiology: Helicobacter pylori Infection
Helicobacter pylori infection is a common chronic bacterial infection of the stomach and is the leading cause of gastritis, peptic ulcer disease, and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. It is a gram-negative, spiral-shaped, microaerophilic organism that colonizes the gastric mucosa and can persist for decades if untreated. Although many infected individuals remain asymptomatic, the organism is associated with significant gastrointestinal morbidity.
Epidemiologically, H. pylori infects more than half of the global population, with a much higher prevalence in developing countries compared to industrialized nations. In developed regions such as the United States, prevalence is approximately 30%, increasing with age, whereas in developing countries it may reach up to 80%, often beginning in childhood. Risk factors are largely related to socioeconomic conditions, including poor sanitation, crowded living environments, and lack of access to clean water. Infection is usually acquired in early childhood and spreads primarily through person-to-person transmission via oral–oral or fecal–oral routes.
The pathophysiology of H. pylori infection is centered on its ability to survive in the acidic gastric environment through the production of urease, which converts urea into ammonia, thereby neutralizing gastric acid. The bacterium colonizes the gastric mucosa, leading to chronic active gastritis characterized by inflammatory cell infiltration. Over time, this can result in mucosal damage, ulcer formation, intestinal metaplasia, and in some cases, malignant transformation. Certain bacterial strains, such as those expressing cytotoxin-associated gene A (cagA), and host genetic factors increase the risk of severe disease.
Clinically, most patients with H. pylori infection are asymptomatic. When symptoms occur, they are usually related to dyspepsia, including upper abdominal pain, bloating, early satiety, and nausea. Alarm features such as weight loss, gastrointestinal bleeding, anemia, persistent vomiting, or progressive dysphagia raise concern for more serious conditions such as peptic ulcer disease or malignancy and require prompt evaluation.
Diagnosis can be made using invasive or non-invasive methods. Non-invasive tests include the urea breath test and fecal antigen test, both of which have high sensitivity and specificity and are commonly used for both diagnosis and confirmation of eradication. Serologic testing is less reliable due to its inability to distinguish between active and past infection. Invasive testing involves endoscopy with biopsy for urease testing, histology, or culture and is recommended in older patients or those with alarm symptoms. Certain medications, such as proton pump inhibitors and antibiotics, may reduce test accuracy and should be discontinued prior to testing.
Treatment of H. pylori infection involves combination therapy to achieve eradication and prevent complications. First-line regimens typically include a proton pump inhibitor combined with antibiotics such as clarithromycin and amoxicillin or metronidazole (triple therapy), or a bismuth-based quadruple regimen including bismuth, tetracycline, metronidazole, and acid suppression therapy. Treatment duration ranges from 10 to 14 days, and eradication rates are influenced by antibiotic resistance patterns. Second-line therapies include alternative antibiotic combinations such as levofloxacin-based regimens.
Follow-up is important to confirm eradication, particularly in patients with persistent symptoms, ulcers, MALT lymphoma, or a history of gastric cancer. Non-invasive tests such as the urea breath test or fecal antigen test are preferred for this purpose. Patient education should emphasize adherence to therapy, as incomplete treatment contributes to treatment failure and resistance.
The prognosis is generally favorable with successful eradication, which significantly reduces the risk of ulcer recurrence and complications. However, untreated infection may lead to chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma. Recurrence rates are low in developed countries but higher in areas with poor sanitation. Common treatment-related side effects include gastrointestinal upset and taste disturbances.
- Published on
Infectious Disease and Microbiology: Hantavirus Pulmonary Syndrome (HPS)
Hantavirus pulmonary syndrome (HPS) is a severe and life-threatening cardiopulmonary disease caused by hantaviruses, most commonly the Sin Nombre virus in North America. First recognized in 1993 in the southwestern United States, the disease is associated with a high mortality rate and rapid clinical deterioration. It primarily affects previously healthy individuals who are exposed to infected rodents.
Epidemiologically, HPS is rare but has been reported in multiple regions across the Americas. Its occurrence is closely linked to the population dynamics of rodents, particularly deer mice and other species such as cotton rats and white-footed mice. Human infection typically results from inhalation of aerosolized particles contaminated with rodent urine, feces, or saliva. Individuals at higher risk include farmers, construction workers, campers, and those cleaning rodent-infested buildings. Although person-to-person transmission is extremely uncommon, it has been reported in certain regions with specific strains such as the Andes virus.
The pathophysiology of HPS involves viral infection of endothelial cells, especially within the lungs, leading to increased vascular permeability. This results in capillary leak syndrome, pulmonary edema, and impaired oxygen exchange. The disease is driven largely by the host immune response rather than direct viral destruction of tissues, leading to pneumonitis, shock, and respiratory failure.
Clinically, the illness begins with a prodromal phase lasting several days, characterized by nonspecific symptoms such as fever, myalgia, fatigue, headache, and sometimes gastrointestinal complaints. This is followed by an abrupt cardiopulmonary phase marked by cough and rapidly progressive shortness of breath, often leading to respiratory failure within a short time. Physical findings include tachypnea, hypoxia, pulmonary crackles, and signs of circulatory shock. Death may occur due to severe hypoxia, shock, or cardiac arrhythmias.
Laboratory evaluation typically reveals leukocytosis with a left shift, thrombocytopenia, hemoconcentration, and atypical lymphocytes. Elevated liver enzymes, creatine phosphokinase, and lactate dehydrogenase are also common. Imaging studies such as chest X-ray or CT scan demonstrate interstitial infiltrates, pulmonary edema, and pleural effusions. Diagnosis is confirmed through serologic testing detecting hantavirus-specific IgM or rising IgG titers, PCR identification of viral RNA, or immunohistochemical detection of viral antigens in tissue samples.
Management of HPS is primarily supportive, as no proven antiviral therapy exists. Patients often require hospitalization and close monitoring, with many needing intensive care, oxygen supplementation, or mechanical ventilation. Broad-spectrum antibiotics are usually started initially until other causes of severe pneumonia are excluded. In critical cases, advanced supportive therapies such as extracorporeal membrane oxygenation (ECMO) may be employed. Prevention relies on minimizing exposure to rodents and their excreta, as no vaccine is currently available.
The prognosis of HPS is guarded, with mortality rates ranging from 35% to 40%, especially in patients with severe disease. Early recognition and aggressive supportive care improve survival. Major complications include acute respiratory distress syndrome, myocardial dysfunction, shock, and death.
- Published on
Ophthalmology – Amblyopia
Amblyopia is a developmental visual disorder characterized by decreased best-corrected visual acuity in one or both eyes that cannot be explained by structural abnormalities of the eye alone. It arises during the critical period of visual development in early childhood, typically within the first decade of life, when abnormal visual input leads to impaired visual processing. Importantly, amblyopia is potentially reversible if detected and treated early. It is the leading cause of monocular visual loss in children and young to middle-aged adults, affecting approximately 2–4% of the population, with a lifetime risk of visual impairment of about 1.2%.
The condition develops due to abnormal visual experience, most commonly from anisometropia (unequal refractive error between the eyes), strabismus (ocular misalignment), or a combination of both. Other causes include high bilateral refractive error or visual deprivation from conditions such as congenital cataracts or ptosis during the critical period. Anisometropia is a particularly strong risk factor, especially when refractive differences exceed certain thresholds. The underlying pathophysiology involves competitive interaction between the eyes, leading to suppression of the weaker eye. This results in structural and functional changes in the visual pathway, including atrophy of neurons in the lateral geniculate nucleus and reduced responsiveness of cortical neurons in the visual cortex.
Patients may present with reduced vision in one eye, although many cases are detected through screening rather than symptoms. In preverbal children, a strong fixation preference for one eye may be noted. Diagnosis requires identification of reduced visual acuity, typically at least a two-line difference between the eyes, in the presence of a risk factor such as anisometropia or strabismus. A key clinical feature is the “crowding phenomenon,” where visual acuity is worse when multiple letters are presented together compared to single optotypes. A comprehensive eye examination, including cycloplegic refraction and assessment for strabismus, is essential to confirm the diagnosis and exclude organic causes of visual loss.
Investigations are generally not required unless there is suspicion of underlying neurological or retinal pathology. In selected cases, optical coherence tomography or electrophysiological tests such as visual evoked potentials or electroretinography may be used to rule out organic disease. The differential diagnosis includes uncorrected refractive error, organic ocular or neurological disease, and poor compliance with treatment.
Management focuses on correcting the underlying cause and promoting use of the amblyopic eye. Initial treatment includes full refractive correction with glasses or contact lenses, which alone may significantly improve vision in many patients. Additional therapy involves occlusion of the dominant eye using patching or pharmacologic penalization with atropine drops to blur the better eye. Both methods have been shown to produce similar improvements in visual acuity. The duration and intensity of treatment depend on the severity of amblyopia and the child’s age, with closer follow-up required in younger patients. Compliance is critical and may require behavioral strategies and parental support.
In cases where amblyopia is secondary to structural abnormalities, such as cataracts or ptosis, surgical correction may be necessary, followed by amblyopia therapy. Alternative methods to traditional patching include Bangerter filters, occlusive contact lenses, or spectacle-mounted occluders. Experimental treatments such as L-Dopa have been studied but are not standard of care.
Regular follow-up is essential to monitor improvement, ensure compliance, and prevent complications such as occlusion amblyopia in the treated eye. Treatment is typically tapered once maximal improvement is achieved. Prognosis is generally favorable, particularly when treatment is initiated before 7 years of age. Many patients achieve significant improvement, with a substantial proportion reaching near-normal vision. However, outcomes depend on factors such as baseline visual acuity, severity of refractive error, and adherence to therapy.
Complications of treatment are uncommon but may include temporary reduction of vision in the patched eye, skin irritation from patches, systemic side effects from atropine, and psychosocial challenges related to treatment. Early detection through routine vision screening and timely intervention remain the most important factors in achieving optimal visual outcomes.
Amblyopia is a developmental visual disorder characterized by decreased best-corrected visual acuity in one or both eyes that cannot be explained by structural abnormalities of the eye alone. It arises during the critical period of visual development in early childhood, typically within the first decade of life, when abnormal visual input leads to impaired visual processing. Importantly, amblyopia is potentially reversible if detected and treated early. It is the leading cause of monocular visual loss in children and young to middle-aged adults, affecting approximately 2–4% of the population, with a lifetime risk of visual impairment of about 1.2%.
The condition develops due to abnormal visual experience, most commonly from anisometropia (unequal refractive error between the eyes), strabismus (ocular misalignment), or a combination of both. Other causes include high bilateral refractive error or visual deprivation from conditions such as congenital cataracts or ptosis during the critical period. Anisometropia is a particularly strong risk factor, especially when refractive differences exceed certain thresholds. The underlying pathophysiology involves competitive interaction between the eyes, leading to suppression of the weaker eye. This results in structural and functional changes in the visual pathway, including atrophy of neurons in the lateral geniculate nucleus and reduced responsiveness of cortical neurons in the visual cortex.
Patients may present with reduced vision in one eye, although many cases are detected through screening rather than symptoms. In preverbal children, a strong fixation preference for one eye may be noted. Diagnosis requires identification of reduced visual acuity, typically at least a two-line difference between the eyes, in the presence of a risk factor such as anisometropia or strabismus. A key clinical feature is the “crowding phenomenon,” where visual acuity is worse when multiple letters are presented together compared to single optotypes. A comprehensive eye examination, including cycloplegic refraction and assessment for strabismus, is essential to confirm the diagnosis and exclude organic causes of visual loss.
Investigations are generally not required unless there is suspicion of underlying neurological or retinal pathology. In selected cases, optical coherence tomography or electrophysiological tests such as visual evoked potentials or electroretinography may be used to rule out organic disease. The differential diagnosis includes uncorrected refractive error, organic ocular or neurological disease, and poor compliance with treatment.
Management focuses on correcting the underlying cause and promoting use of the amblyopic eye. Initial treatment includes full refractive correction with glasses or contact lenses, which alone may significantly improve vision in many patients. Additional therapy involves occlusion of the dominant eye using patching or pharmacologic penalization with atropine drops to blur the better eye. Both methods have been shown to produce similar improvements in visual acuity. The duration and intensity of treatment depend on the severity of amblyopia and the child’s age, with closer follow-up required in younger patients. Compliance is critical and may require behavioral strategies and parental support.
In cases where amblyopia is secondary to structural abnormalities, such as cataracts or ptosis, surgical correction may be necessary, followed by amblyopia therapy. Alternative methods to traditional patching include Bangerter filters, occlusive contact lenses, or spectacle-mounted occluders. Experimental treatments such as L-Dopa have been studied but are not standard of care.
Regular follow-up is essential to monitor improvement, ensure compliance, and prevent complications such as occlusion amblyopia in the treated eye. Treatment is typically tapered once maximal improvement is achieved. Prognosis is generally favorable, particularly when treatment is initiated before 7 years of age. Many patients achieve significant improvement, with a substantial proportion reaching near-normal vision. However, outcomes depend on factors such as baseline visual acuity, severity of refractive error, and adherence to therapy.
Complications of treatment are uncommon but may include temporary reduction of vision in the patched eye, skin irritation from patches, systemic side effects from atropine, and psychosocial challenges related to treatment. Early detection through routine vision screening and timely intervention remain the most important factors in achieving optimal visual outcomes.
- Published on
Ophthalmology – Amaurosis Fugax
Amaurosis fugax refers to transient monocular vision loss caused by temporary ischemia or vascular insufficiency affecting the retina or optic nerve. It is often described as a sudden, painless loss of vision in one eye that typically lasts seconds to minutes and resolves completely. Patients frequently describe the experience as a “curtain” descending over the visual field, most commonly affecting the upper field, although other patterns such as patchy or sectoral vision loss may occur. Recurrent episodes often follow a similar pattern. This condition is clinically significant because it is often a warning sign of underlying vascular disease and an increased risk of stroke.
Approximately 50,000 new cases occur annually in the United States, and major risk factors include hypertension, hypercholesterolemia, diabetes, and smoking. The underlying pathophysiology involves transient interruption of blood flow to the retina or optic nerve. The most common mechanism is thromboembolism, typically originating from atherosclerotic plaques in the ipsilateral carotid artery or from cardiac sources such as valvular disease or intracardiac thrombi. Other mechanisms include hemodynamic compromise due to reduced perfusion, vasospasm (as in retinal migraine), or abnormalities in blood viscosity or coagulability. Ocular causes such as anterior ischemic optic neuropathy, central retinal vein occlusion, or severe hypertension may also present with similar transient visual symptoms.
A detailed history is critical to confirm the diagnosis and distinguish it from other causes of transient vision loss. Key features include sudden onset, monocular involvement, brief duration, and complete recovery. Associated symptoms suggestive of systemic conditions, particularly giant cell arteritis in patients over 55 years old, should be actively sought, including scalp tenderness, jaw claudication, fever, weight loss, and muscle weakness. Physical examination should include measurement of blood pressure, cardiac and carotid auscultation, and palpation of temporal arteries. A comprehensive ophthalmic examination is essential to evaluate for signs of retinal ischemia, such as pallor, hemorrhages, cotton wool spots, or visible emboli such as Hollenhorst plaques.
Urgent diagnostic evaluation is required to identify the underlying cause and reduce the risk of stroke. Laboratory tests include complete blood count, inflammatory markers such as ESR and CRP to rule out giant cell arteritis, lipid profile, and diabetes screening. In selected cases, evaluation for hypercoagulable states may be indicated. Imaging studies are crucial, with carotid duplex ultrasound used to assess for carotid artery stenosis or plaque. Additional imaging such as CT or MR angiography may be performed to evaluate cerebral and vascular anatomy. Cardiac evaluation with echocardiography and electrocardiography is important to identify potential embolic sources. Fluorescein angiography may be used to document retinal ischemia in uncertain cases.
Management focuses on preventing future ischemic events, particularly stroke. Antiplatelet therapy, such as aspirin, is commonly used to reduce the risk of recurrent events. Control of modifiable risk factors, including blood pressure, cholesterol, and smoking cessation, is essential. In cases of carotid artery stenosis, treatment depends on the severity: medical management for mild to moderate stenosis, and carotid endarterectomy for significant stenosis, particularly when greater than 70% or associated with symptoms. If a cardiac source is identified, appropriate management such as anticoagulation may be required. In suspected giant cell arteritis, immediate initiation of high-dose corticosteroids is critical to prevent permanent vision loss.
The prognosis depends on the underlying cause and timely intervention. Amaurosis fugax is an important predictor of future stroke, with an estimated annual stroke risk of approximately 2%. With appropriate treatment, including surgical intervention when indicated, the risk of stroke can be significantly reduced. However, procedures such as carotid endarterectomy carry their own risks, including stroke and death. Overall, prompt recognition and comprehensive systemic evaluation are essential to prevent serious neurological complications.
Amaurosis fugax refers to transient monocular vision loss caused by temporary ischemia or vascular insufficiency affecting the retina or optic nerve. It is often described as a sudden, painless loss of vision in one eye that typically lasts seconds to minutes and resolves completely. Patients frequently describe the experience as a “curtain” descending over the visual field, most commonly affecting the upper field, although other patterns such as patchy or sectoral vision loss may occur. Recurrent episodes often follow a similar pattern. This condition is clinically significant because it is often a warning sign of underlying vascular disease and an increased risk of stroke.
Approximately 50,000 new cases occur annually in the United States, and major risk factors include hypertension, hypercholesterolemia, diabetes, and smoking. The underlying pathophysiology involves transient interruption of blood flow to the retina or optic nerve. The most common mechanism is thromboembolism, typically originating from atherosclerotic plaques in the ipsilateral carotid artery or from cardiac sources such as valvular disease or intracardiac thrombi. Other mechanisms include hemodynamic compromise due to reduced perfusion, vasospasm (as in retinal migraine), or abnormalities in blood viscosity or coagulability. Ocular causes such as anterior ischemic optic neuropathy, central retinal vein occlusion, or severe hypertension may also present with similar transient visual symptoms.
A detailed history is critical to confirm the diagnosis and distinguish it from other causes of transient vision loss. Key features include sudden onset, monocular involvement, brief duration, and complete recovery. Associated symptoms suggestive of systemic conditions, particularly giant cell arteritis in patients over 55 years old, should be actively sought, including scalp tenderness, jaw claudication, fever, weight loss, and muscle weakness. Physical examination should include measurement of blood pressure, cardiac and carotid auscultation, and palpation of temporal arteries. A comprehensive ophthalmic examination is essential to evaluate for signs of retinal ischemia, such as pallor, hemorrhages, cotton wool spots, or visible emboli such as Hollenhorst plaques.
Urgent diagnostic evaluation is required to identify the underlying cause and reduce the risk of stroke. Laboratory tests include complete blood count, inflammatory markers such as ESR and CRP to rule out giant cell arteritis, lipid profile, and diabetes screening. In selected cases, evaluation for hypercoagulable states may be indicated. Imaging studies are crucial, with carotid duplex ultrasound used to assess for carotid artery stenosis or plaque. Additional imaging such as CT or MR angiography may be performed to evaluate cerebral and vascular anatomy. Cardiac evaluation with echocardiography and electrocardiography is important to identify potential embolic sources. Fluorescein angiography may be used to document retinal ischemia in uncertain cases.
Management focuses on preventing future ischemic events, particularly stroke. Antiplatelet therapy, such as aspirin, is commonly used to reduce the risk of recurrent events. Control of modifiable risk factors, including blood pressure, cholesterol, and smoking cessation, is essential. In cases of carotid artery stenosis, treatment depends on the severity: medical management for mild to moderate stenosis, and carotid endarterectomy for significant stenosis, particularly when greater than 70% or associated with symptoms. If a cardiac source is identified, appropriate management such as anticoagulation may be required. In suspected giant cell arteritis, immediate initiation of high-dose corticosteroids is critical to prevent permanent vision loss.
The prognosis depends on the underlying cause and timely intervention. Amaurosis fugax is an important predictor of future stroke, with an estimated annual stroke risk of approximately 2%. With appropriate treatment, including surgical intervention when indicated, the risk of stroke can be significantly reduced. However, procedures such as carotid endarterectomy carry their own risks, including stroke and death. Overall, prompt recognition and comprehensive systemic evaluation are essential to prevent serious neurological complications.
- Published on
Ophthalmology – Alport Syndrome
Alport syndrome is a hereditary disorder characterized by a triad of progressive kidney disease (glomerulonephritis), sensorineural hearing loss, and ocular abnormalities. It is caused by mutations affecting type IV collagen, an essential structural component of basement membranes in the kidney, cochlea, cornea, and retina. The condition most commonly follows an X-linked recessive inheritance pattern, with mutations in the COL4A5 gene, although autosomal recessive and dominant forms involving COL4A3 and COL4A4 also occur. It affects approximately 1 in 5,000 individuals, with males more severely affected, and many patients progressing to end-stage renal failure and significant hearing loss by around 40 years of age.
The underlying pathophysiology involves structural abnormalities in basement membranes due to defective type IV collagen, leading to progressive dysfunction of affected organs. In the kidneys, this results in chronic glomerulonephritis, while in the inner ear it leads to high-frequency hearing loss that gradually worsens. In the eye, abnormalities arise from similar structural defects affecting ocular tissues.
Patients often present initially with hematuria, which may be microscopic in childhood or episodic gross hematuria associated with infections. Over time, proteinuria, nephrotic syndrome, hypertension, and eventual renal failure may develop. Hearing loss typically begins in late childhood or adolescence and progresses over time. Ocular manifestations are diverse and can provide important diagnostic clues. The most characteristic findings include anterior lenticonus, which is highly suggestive of Alport syndrome, and a dot-and-fleck retinopathy, which is usually asymptomatic. Posterior polymorphous corneal dystrophy may also be present. Other ocular findings include cataracts, corneal abnormalities, retinal pigmentation changes, microcornea, and rarely spontaneous lens rupture.
Diagnosis is based on a combination of clinical features, family history, and investigations. Urinalysis typically reveals hematuria and proteinuria, while blood tests assess renal function. Audiometry detects sensorineural hearing loss, and ophthalmologic examination identifies characteristic eye findings. Renal biopsy may show changes in the glomerular basement membrane, particularly thickening and irregularity on electron microscopy. Genetic testing can confirm the diagnosis and identify carriers within families.
The differential diagnosis depends on the presenting features and includes other causes of hereditary nephritis, retinopathies, and corneal dystrophies. For example, dot-and-fleck retinopathy must be distinguished from other retinal conditions, and anterior lenticonus must be differentiated from more common lens changes such as nuclear sclerosis.
Management is multidisciplinary and focuses on supportive care and treatment of complications. Renal disease may require dialysis or kidney transplantation in advanced stages. Hearing aids are used for auditory impairment. Ocular management includes correction of refractive errors, cataract surgery if needed, and monitoring of corneal conditions. Retinal findings typically do not require treatment as they are usually asymptomatic.
Regular follow-up with ophthalmology, nephrology, and audiology is essential, and family members should be screened for early signs such as microscopic hematuria. The prognosis varies depending on the genetic subtype, but males with X-linked disease often experience progressive renal failure and hearing loss, while females may have milder disease. Visual prognosis is generally good, although some patients may develop vision-threatening complications. Overall, morbidity is largely driven by renal and auditory involvement, with ocular findings serving as important diagnostic markers.
Alport syndrome is a hereditary disorder characterized by a triad of progressive kidney disease (glomerulonephritis), sensorineural hearing loss, and ocular abnormalities. It is caused by mutations affecting type IV collagen, an essential structural component of basement membranes in the kidney, cochlea, cornea, and retina. The condition most commonly follows an X-linked recessive inheritance pattern, with mutations in the COL4A5 gene, although autosomal recessive and dominant forms involving COL4A3 and COL4A4 also occur. It affects approximately 1 in 5,000 individuals, with males more severely affected, and many patients progressing to end-stage renal failure and significant hearing loss by around 40 years of age.
The underlying pathophysiology involves structural abnormalities in basement membranes due to defective type IV collagen, leading to progressive dysfunction of affected organs. In the kidneys, this results in chronic glomerulonephritis, while in the inner ear it leads to high-frequency hearing loss that gradually worsens. In the eye, abnormalities arise from similar structural defects affecting ocular tissues.
Patients often present initially with hematuria, which may be microscopic in childhood or episodic gross hematuria associated with infections. Over time, proteinuria, nephrotic syndrome, hypertension, and eventual renal failure may develop. Hearing loss typically begins in late childhood or adolescence and progresses over time. Ocular manifestations are diverse and can provide important diagnostic clues. The most characteristic findings include anterior lenticonus, which is highly suggestive of Alport syndrome, and a dot-and-fleck retinopathy, which is usually asymptomatic. Posterior polymorphous corneal dystrophy may also be present. Other ocular findings include cataracts, corneal abnormalities, retinal pigmentation changes, microcornea, and rarely spontaneous lens rupture.
Diagnosis is based on a combination of clinical features, family history, and investigations. Urinalysis typically reveals hematuria and proteinuria, while blood tests assess renal function. Audiometry detects sensorineural hearing loss, and ophthalmologic examination identifies characteristic eye findings. Renal biopsy may show changes in the glomerular basement membrane, particularly thickening and irregularity on electron microscopy. Genetic testing can confirm the diagnosis and identify carriers within families.
The differential diagnosis depends on the presenting features and includes other causes of hereditary nephritis, retinopathies, and corneal dystrophies. For example, dot-and-fleck retinopathy must be distinguished from other retinal conditions, and anterior lenticonus must be differentiated from more common lens changes such as nuclear sclerosis.
Management is multidisciplinary and focuses on supportive care and treatment of complications. Renal disease may require dialysis or kidney transplantation in advanced stages. Hearing aids are used for auditory impairment. Ocular management includes correction of refractive errors, cataract surgery if needed, and monitoring of corneal conditions. Retinal findings typically do not require treatment as they are usually asymptomatic.
Regular follow-up with ophthalmology, nephrology, and audiology is essential, and family members should be screened for early signs such as microscopic hematuria. The prognosis varies depending on the genetic subtype, but males with X-linked disease often experience progressive renal failure and hearing loss, while females may have milder disease. Visual prognosis is generally good, although some patients may develop vision-threatening complications. Overall, morbidity is largely driven by renal and auditory involvement, with ocular findings serving as important diagnostic markers.
- Published on
Click here to start customizing
- Published on
Infectious Disease and Microbiology: Granuloma Inguinale (Donovanosis)
Granuloma inguinale, also known as donovanosis, is a chronic sexually transmitted infection characterized by progressive ulcerative lesions of the genital and perineal regions. It may present as a single lesion or multiple nodules that gradually enlarge and ulcerate. The disease is caused by Klebsiella granulomatis, a Gram-negative intracellular organism that is difficult to culture in laboratory settings.
Epidemiologically, granuloma inguinale is endemic in tropical and developing regions such as India, Papua New Guinea, central Australia, and southern Africa, while it remains rare in developed countries, including the United States. The primary risk factor is geographic exposure through residence, work, or travel in endemic areas. Transmission occurs via sexual contact, and preventive measures mainly involve the use of barrier contraceptives.
Following an incubation period of approximately 2–3 weeks, patients typically develop painless nodules on the genitalia that progressively enlarge and ulcerate. These ulcers are classically described as beefy-red, highly vascular, and prone to bleeding on contact. Unlike many other sexually transmitted infections, regional lymphadenopathy is usually absent. However, subcutaneous spread of infection may result in pseudobuboes. In some cases, verrucous lesions may develop in the perianal area, and advanced disease can lead to scarring and deformities.
Diagnosis is primarily clinical, supported by identification of characteristic “Donovan bodies,” which are intracellular organisms seen in tissue smears or biopsy specimens. The organism is notoriously difficult to culture, and widely available PCR testing is lacking. It is also important to assess for coexisting sexually transmitted infections, as coinfection is common. Differential diagnosis includes infections such as genital herpes, syphilis, chancroid, and lymphogranuloma venereum, as well as noninfectious conditions like malignancy and inflammatory dermatoses.
Treatment requires prolonged antibiotic therapy. First-line treatment consists of Doxycycline administered orally for at least three weeks and continued until complete healing of lesions. Alternative options include azithromycin, ciprofloxacin, erythromycin, and trimethoprim–sulfamethoxazole. In cases with poor response or in immunocompromised patients, an aminoglycoside such as gentamicin may be added. Special considerations are necessary in pregnancy, where erythromycin is preferred due to contraindications of certain antibiotics.
Follow-up is essential to ensure complete resolution, as healing typically occurs from the margins inward and relapses may occur months after treatment. Sexual contacts within the preceding 60 days should be evaluated and managed appropriately. Although prognosis is generally favorable with treatment, complications can include genital pseudoelephantiasis, significant tissue destruction, and, rarely, deep infections such as psoas abscess.
